AGIO (Agios Pharmaceuticals) Short Ratio


AGIO Agios Pharmaceuticals Inc AGIO
49 GF Score
Price $41.23
GF Value $84.50
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Agios Pharmaceuticals Short Ratio?

Short Ratio is a metric signaling prevailing investors' sentiment with a company. It represents the number of days it takes short sellers on average to repurchase all the shares short.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

AGIO
49GF Score
Agios Pharmaceuticals Inc AGIO
Short Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Agios Pharmaceuticals (AGIO) Overvalued in 2026?

Based on GuruFocus' analysis, Agios Pharmaceuticals stock appears to be undervalued. The current stock price of $41.23 is trading 51.2% below its estimated GF Value™ of $84.50. GuruFocus considers Agios Pharmaceuticals to be Possible Value Trap.

Key valuation signals for AGIO:

  • Short Ratio:
  • GF Value™: $84.50 vs. price of $41.23 (51.2% below fair value)
  • GF Score™: 49/100 with 5 warning signs

No single metric tells the full story. See the AGIO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Agios Pharmaceuticals Business Description

Other Exchanges 0HB0:UK8AP:Germany
Address 88 Sidney Street, Cambridge, MA, USA, 02139
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.
49GF Score

Get the complete analysis for AGIO

Short Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$41.23
Price
$84.50
GF Value